Physician profile
David Brown
NPI 1720246689
$6,615.01
in general payments reported to CMS, 2019-2025
29 companies · $1,954 in 2025
The $1,954 reported for 2025 was more than what 89% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $282 · 2021: $229 · 2022: $1,026 · 2023: $992 · 2024: $1,793 · 2025: $1,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,988 · Consulting Fee: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,988.38 |
| Consulting Fee | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $2,147.21 | 2022-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Inspire Medical Systems, INC. | $1,591.43 | 2021-2025 | Inspire |
| Medtronic, INC. | $710.75 | 2024-2025 | Propel, Sinuva, Nim Vital |
| Optinose US, INC. | $413.74 | 2019-2023 | |
| Acclarent, INC | $253.61 | 2019-2022 | |
| Genzyme Corporation | $222.53 | 2023-2025 | |
| Glaxosmithkline, LLC. | $189.02 | 2022-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Aerin Medical INC. | $102.65 | 2022-2023 | |
| Intuitive Surgical, INC. | $97.67 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $87.96 | 2020-2023 | Dupixent |
| Stryker Corporation | $87.41 | 2019-2022 | |
| Grifols USA, LLC | $82.42 | 2024-2025 | Xembify |
| Organogenesis INC. | $72.94 | 2023 | Puraply |
| Takeda Pharmaceuticals U.S.A., INC. | $62.36 | 2024 | Takhzyro |
| Smith+Nephew, INC. | $53.60 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $51.44 | 2022-2024 | Haegarda |
| Tactile Systems Technology INC | $47.98 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $45.84 | 2025 | Airsupra |
| Alk-Abello, INC | $41.74 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $41.45 | 2022 | |
| Hikma Pharmaceuticals USA | $36.75 | 2023 | Ryaltris |
| Biofire Diagnostics, LLC | $35.84 | 2019 | |
| Biocryst US Sales Co., LLC | $27.40 | 2025 | Orladeyo |
| Kaleo, INC. | $24.59 | 2022 | |
| Pharming Healthcare, INC. | $23.82 | 2023 | Ruconest |
| Intersect Ent, INC. | $21.60 | 2021 | |
| Leo Pharma INC. | $14.97 | 2022 | |
| Pfizer INC. | $14.40 | 2023 | |
| Aimmune Therapeutics, INC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.